ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism? [Anatol J Cardiol]
Anatol J Cardiol. 2017; 18(1): 77-79 | DOI: 10.14744/AnatolJCardiol.2017.7805

Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?

Marija Vavlukis, Irina Kotlar, Hajber Taravari, Lidija Poposka, Sasko Kedev
University Clinic of Cardiology, Medical Faculty, University Ss' Cyril and Methodius; Skopje-Republic of Macedonia






Marija Vavlukis, Irina Kotlar, Hajber Taravari, Lidija Poposka, Sasko Kedev. Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?. Anatol J Cardiol. 2017; 18(1): 77-79

Corresponding Author: Marija Vavlukis, Macedonia
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.